International Rett Syndrome Foundation

IRSF relies on a 20-member scientific advisory board that reviews applications through a peer-review process mirroring NIH study sections. The foundation prioritizes proposals with clear translational potential — those that can move from academic bench to clinical trial within a defined window — and increasingly weights applications that include parent-reported outcome measures from its own Centers of Excellence network.

The foundation deploys both traditional investigator-initiated grants and venture-philanthropy capital through vehicles like the Rett Syndrome Innovation Fund, launched in 2023. The Innovation Fund operates alongside biotech partners Acadia Pharmaceuticals and Neurogene and is structured to take equity positions or convertible notes in companies advancing Rett-specific therapies, allowing any eventual returns to recycle back into the research pipeline.

IRSF and the Rett Syndrome Research Trust (RSRT) are separate organizations with distinct funding philosophies. IRSF emerged from a 2007 merger and funds both research and clinical infrastructure, while RSRT, based in Connecticut, runs an independent grant program focused exclusively on curative research. The two foundations occasionally co-fund projects but maintain separate scientific advisory panels and fundraising operations.

IRSF participates in FDA patient-focused drug development meetings and has organized caregiver panels that inform regulatory endpoints for clinical trials. Through its advocacy arm, the foundation has helped secure tens of millions in directed NIH Rett syndrome research funding, and its natural-history database — populated by the Centers of Excellence — has been used as a historical control arm in at least one neurotherapeutics application.

The foundation's portfolio spans gene therapy (direct MECP2 replacement or augmentation), RNA editing and antisense oligonucleotide approaches, MECP2 reactivation compounds (aimed at the silent copy of the gene resident on the inactivated X chromosome), and symptomatic pharmacology for seizure control, respiratory dysfunction, and autonomic instability. Gene therapy and reactivation strategies receive the largest allocation.